A 42-year-old Indian woman presents with a 6-week history of progressive dyspnea, hemoptysis, and sinusitis. Examination reveals upper respiratory tract ulceration. Chest X-ray shows bilateral cavitary lung lesions. Serum creatinine is 3.2 mg/dL with active urinary sediment (RBC casts). c-ANCA is positive with anti-PR3 antibodies. What is the most appropriate next step in management?

Explanation

## Management of Generalized GPA with Renal Involvement ### Diagnosis: GPA (Granulomatosis with Polyangiitis) **Key Point:** This patient has **generalized GPA** with the classic triad of upper respiratory (sinusitis, ulceration), lower respiratory (hemoptysis, cavitary disease), and renal involvement (glomerulonephritis with RBC casts). c-ANCA/anti-PR3 positivity confirms the diagnosis. ### Disease Severity Assessment | Feature | Severity Implication | |---------|----------------------| | Cavitary lung disease | Moderate-to-severe | | Glomerulonephritis with RBC casts | Severe (risk of ESRD) | | Hemoptysis | Alveolar hemorrhage (life-threatening) | | Multi-organ involvement | Generalized disease | | Elevated creatinine (3.2 mg/dL) | Acute kidney injury | **High-Yield:** GPA is classified as: - **Localized:** Upper respiratory only - **Early systemic:** Upper + lower respiratory, no renal disease - **Generalized:** Multi-organ with renal involvement (THIS CASE) ### Treatment Algorithm for Generalized GPA ```mermaid flowchart TD A[Generalized GPA diagnosed]:::outcome --> B{Organ-threatening disease?}:::decision B -->|Yes: Renal/pulmonary hemorrhage| C[Induction therapy]:::action C --> D[IV methylprednisolone 1g daily x 3 days]:::action D --> E[Oral prednisolone 1 mg/kg/day]:::action E --> F[Cyclophosphamide 15 mg/kg IV monthly OR rituximab]:::action F --> G[Remission achieved at 3-6 months]:::outcome G --> H[Switch to maintenance: azathioprine or rituximab]:::action B -->|No: Localized disease| I[Oral prednisolone + cyclophosphamide]:::action ``` ### Rationale for IV Methylprednisolone + Cyclophosphamide 1. **Induction Phase (0–3–6 months):** - IV methylprednisolone 1 g daily for 3 days (pulse therapy for rapid anti-inflammatory effect) - Followed by oral prednisolone 1 mg/kg/day, tapered over weeks - Cyclophosphamide 15 mg/kg IV monthly (or 2 mg/kg/day oral) for 3–6 months 2. **Mechanism:** - Corticosteroids suppress immune response and reduce inflammation - Cyclophosphamide is a **nitrogen mustard alkylating agent** that depletes B and T cells — essential for ANCA-associated vasculitis remission 3. **Maintenance Phase (after remission):** - Switch to azathioprine (2 mg/kg/day) or rituximab (375 mg/m² IV weekly x 4) to prevent relapse **Clinical Pearl:** Cyclophosphamide carries significant toxicity (hemorrhagic cystitis, infertility, secondary malignancy). Mesna is co-administered as uroprotection. Rituximab is increasingly preferred in modern practice as an alternative induction agent with better safety profile. ### Why Monotherapy Fails **Warning:** Prednisolone monotherapy (option B) is **inadequate** for generalized GPA with renal involvement. Untreated glomerulonephritis progresses to ESRD within weeks. Immunosuppression with cyclophosphamide or rituximab is mandatory. ### Plasmapheresis Indication Plasmapheresis (option C) is reserved for **pulmonary hemorrhage with hypoxemia** or **rapidly progressive glomerulonephritis with creatinine >5.8 mg/dL or oliguria**. While this patient has hemoptysis and elevated creatinine, plasmapheresis is NOT the first-line induction agent — it is an **adjunctive** therapy in fulminant cases. **Mnemonic: ANCA Vasculitis Induction (GPA/MPA)** - **I**V methylprednisolone (pulse) - **C**yclophosphamide or rituximab (B-cell depletion) - **A**zathioprine (maintenance, later) - **N**o monotherapy - **C**lose monitoring (CBC, creatinine, urinalysis) - **A**void infections (Pneumocystis prophylaxis with TMP-SMX) [cite:Harrison 21e Ch 328; EULAR 2016 GPA Guidelines]